BMRA logo

Biomerica (BMRA) Stock

Profile

Sector:

Healthcare

Industry:

Medical Devices

Country:

United States

IPO:

07 September 1984

Indexes:

Not included

Website:

http://www.biomerica.com

Description:

Biomerica (BMRA) is a biotechnology company that develops and sells diagnostic tests for various health conditions. Their products help in the early detection of diseases, focusing on areas like gastrointestinal health and autoimmune disorders. Biomerica aims to improve patient care through innovative testing solutions.

Key Details

Price

$0.45

Market Cap

$7.56 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$5.42 M(+1.42% YoY)

Annual EPS

-$0.36(+28.00% YoY)

PE Ratio

-

Annual ROE

-65.28%

Annual Debt To Equity

0.00

Beta

0.86

Events Calendar

Earnings

Next earnings date:

Jan 16, 2025

Recent quarterly earnings:

Oct 16, 2024

Recent annual earnings:

Aug 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Apr 07, 2016

Analyst ratings

Recent major analysts updates

19 Oct '20 Aegis Capital
Buy
04 Sept '20 Aegis Capital
Buy
21 Aug '20 Aegis Capital
Buy
17 Dec '18 B. Riley Securities
Buy
17 Dec '18 B. Riley FBR
Buy

Screeners with BMRA included

Small cap stocks
NASDAQ earnings calendar
Biggest stock gainers today
Stocks cheaper than 1 dollar
Stocks below SMA 200
Most recommended stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.45
BMRA price is $0.45

Price YTD Change

-62.24%
BMRA price is down -62.24% since January 1st

Price All-time High

$16.00
BMRA price is currently -97.19% below its historical high of $16.00

Market Cap

$7.56 M
BMRA market capitalization is $7.56 million

Beta

0.86
BMRA beta is 0.86

200-day SMA

$0.55
BMRA 200-day simple moving average is currently -18.68% below its 200-day simple moving average

14-day RSI

44.92
BMRA 14-day relative strength index is 44.92

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

-24.78%
BMRA annual revenue is down -24.78% over the past 3 years

Annual Net Income 3-Year Change

+19.72%
BMRA annual net profit is up +19.72% over the past 3 years

Annual EPS 3-Year Change

+41.94%
BMRA annual earnings per share is up +41.94% over the past 3 years

Annual Gross Profit

$611.00 K
BMRA annual gross profit is $611.00 thousand

Annual Operating Profit

-$6.37 M
BMRA annual operaing income is -$6.37 million

Annual Operating Profit 3-Year Change

+15.1%
BMRA annual operaing income is up +15.1% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Gross Margin Sector Rank

10.11%
BMRA annual gross profit margin is higher than 10.11% of companies in Healthcare sector

Annual Operating Margin Sector Rank

42.04%
BMRA annual operating profit margin is higher than 42.04% of companies in Healthcare sector

Annual Net Margin Sector Rank

43.62%
BMRA annual net profit margin is higher than 43.62% of companies in Healthcare sector

Annual ROE

-65.28%
BMRA annual return on equity is -65.28%

Annual ROA

-50.43%
BMRA annual return on assets is -50.43%

Annual EBIT

-$6.37 M
BMRA annual earnings before interest & taxes is -$6.37 million

Annual EBITDA

-$5.99 M
BMRA annual earnings before interest, taxes, depreciation & amortization is -$5.99 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PB Ratio Sector Rank

45.67%
BMRA price to book ratio is higher than 45.67% of companies in Healthcare sector

PS Ratio Sector Rank

27.82%
BMRA price to sales ratio is higher than 27.82% of companies in Healthcare sector

Enterprise Value

$5.45 M
BMRA enterprise value is $5.45 million

Enterprise Value 1-Year Change

-38.35%
BMRA enterprise value is down -38.35% year-on-year

EV/EBITDA

-0.89
BMRA EV/EBITDA is -0.89

EV/EBITDA Sector Rank

50.98%
BMRA EV/EBITDA is higher than 50.98% of companies in Healthcare sector

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Debt To Equity Sector Rank

47.84%
BMRA annual debt to equity ratio is higher than 47.84% of companies in Healthcare sector

Annual Quick Ratio

2.43
BMRA annual quick ratio is 2.43

Annual Quick Ratio Sector Rank

56.08%
BMRA annual quick ratio is higher than 56.08% of companies in Healthcare sector

Annual Current Ratio

3.51
BMRA annual current ratio is 3.51

Annual Current Ratio Sector Rank

51.99%
BMRA annual current ratio is higher than 51.99% of companies in Healthcare sector

Annual Total Assets

$9.25 M
BMRA annual total assets is $9.25 million

Annual Current Assets

$7.73 M
BMRA annual total current assets is $7.73 million

Annual Total Liabilities

$2.66 M
BMRA annual total liabilities is $2.66 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

-2.08%
BMRA annual cash flow from operations is down -2.08% over the past 3 years

Annual CFI 3-Year Change

+61.1%
BMRA annual cash flow from investing activities is up +61.1% over the past 3 years

Annual CFF 3-Year Change

-107.27%
BMRA annual cash flow from financing activities is down -107.27% over the past 3 years

Annual CAPEX

$115.00 K
BMRA annual capital expenditures is $115.00 thousand

Annual CAPEX 3-Year Change

-61.1%
BMRA annual capital expenditures is down -61.1% over the past 3 years

Annual FCF

-$5.48 M
BMRA annual free cash flow is -$5.48 million

Annual FCF 3-Year Change

+1.29%
BMRA annual free cash flow is up +1.29% over the past 3 years

Institutional Ownership

Similar stocks

BFRI logo
Biofrontera (BFRI)
INBS logo
Intelligent Bio Solutions (INBS)
OTRK logo
Ontrak (OTRK)
PSTV logo
Plus Therapeutics (PSTV)
MBRX logo
Moleculin Biotech (MBRX)
ZCMD logo
Zhongchao (ZCMD)
GLTO logo
Galecto (GLTO)
TNON logo
Tenon Medical (TNON)
SYRS logo
Syros Pharmaceuticals (SYRS)
Biomerica Reports First Quarter Fiscal 2025 Financial Results
Biomerica Reports First Quarter Fiscal 2025 Financial Results
Biomerica Reports First Quarter Fiscal 2025 Financial Results
BMRA
globenewswire.com16 October 2024

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024.

The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
BMRA
globenewswire.com04 September 2024

- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country.

Biomerica Reports Fiscal 2024 Year End Results
Biomerica Reports Fiscal 2024 Year End Results
Biomerica Reports Fiscal 2024 Year End Results
BMRA
globenewswire.com29 August 2024

IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales to $5.4 million, compared to $5.3 million in the prior year. This growth was primarily driven by strong demand for EZ Detect™ colorectal screening tests and Aware® breast self-exam products in the Middle East including the United Arab Emirates.

Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
Biomerica Launches At-Home Sample Collection for inFoods® IBS, Significantly Expanding Access for Millions of IBS Sufferers
BMRA
globenewswire.com01 July 2024

IRVINE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, is proud to announce a major enhancement to its inFoods® IBS system, aimed at simplifying and transforming the patient experience.

FAQ

  • What is the primary business of Biomerica?
  • What is the ticker symbol for Biomerica?
  • Does Biomerica pay dividends?
  • What sector is Biomerica in?
  • What industry is Biomerica in?
  • What country is Biomerica based in?
  • When did Biomerica go public?
  • Is Biomerica in the S&P 500?
  • Is Biomerica in the NASDAQ 100?
  • Is Biomerica in the Dow Jones?
  • When was Biomerica's last earnings report?
  • When does Biomerica report earnings?
  • Should I buy Biomerica stock now?

What is the primary business of Biomerica?

Biomerica (BMRA) is a biotechnology company that develops and sells diagnostic tests for various health conditions. Their products help in the early detection of diseases, focusing on areas like gastrointestinal health and autoimmune disorders. Biomerica aims to improve patient care through innovative testing solutions.

What is the ticker symbol for Biomerica?

The ticker symbol for Biomerica is NASDAQ:BMRA

Does Biomerica pay dividends?

No, Biomerica does not pay dividends

What sector is Biomerica in?

Biomerica is in the Healthcare sector

What industry is Biomerica in?

Biomerica is in the Medical Devices industry

What country is Biomerica based in?

Biomerica is headquartered in United States

When did Biomerica go public?

Biomerica's initial public offering (IPO) was on 07 September 1984

Is Biomerica in the S&P 500?

No, Biomerica is not included in the S&P 500 index

Is Biomerica in the NASDAQ 100?

No, Biomerica is not included in the NASDAQ 100 index

Is Biomerica in the Dow Jones?

No, Biomerica is not included in the Dow Jones index

When was Biomerica's last earnings report?

Biomerica's most recent earnings report was on 16 October 2024

When does Biomerica report earnings?

The next expected earnings date for Biomerica is 16 January 2025

Should I buy Biomerica stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions